» Articles » PMID: 28476684

MiR-26a and MiR-26b Inhibit Esophageal Squamous Cancer Cell Proliferation Through Suppression of C-MYC Pathway

Overview
Journal Gene
Specialty Molecular Biology
Date 2017 May 7
PMID 28476684
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Dysregulation of c-Myc is one of the most common abnormalities in human malignancies, including esophageal cancer, one of the world's most lethal cancers. MicroRNA-26 family, including miR-26a and miR-26b, is transcriptionally suppressed by c-MYC. Our previous microarray data indicated a decreased-expression of miR-26 family in esophageal squamous cell carcinoma (ESCC). However, its roles in c-MYC pathway regulation and esophageal cancer tumorigenesis have yet not been elucidated. In this study, we expanded the detection of miR-26 expression in ESCC patients and found that the great majority of ESCC tissues showed an >50% reduction, even in the early-staged tumor. Furthermore, ectopic expression of miR-26a or miR-26b induced ESCC cell growth inhibition and G1 phase arrest. MYC binding protein (MYCBP) was identified as a direct target of miR-26. MiR-26 could dramatically decrease MYCBP mRNA and protein levels, as well as the expression of luciferase carrying MYCBP 3'-untranslated region. Moreover, knock-down of MYCBP mimicked the effect of miR-26. More importantly, miR-26 overexpression could downregulate a series of c-MYC target genes as MYCBP silence did. Taken together, these results indicate that miR-26 family can suppress esophageal cancer cell proliferation by inhibition of MYCBP, subsequently downregulate c-MYC pathway. Besides, we also found that reduction of miR-26 expression in ESCC was not due to DNA methylation. Hence, our study reveals a novel feedback loop for c-MYC pathway and implicates miR-26 as a potential target for prevention and treatment of esophageal cancer.

Citing Articles

miR-1301-3p promotes invasion and migration and EMT progression in esophageal cancer by downregulating NBL1 expression.

Du J, Zhang S, Zhang X, Yang Z, Xue S, Xu G Thorac Cancer. 2023; 14(30):3032-3041.

PMID: 37680006 PMC: 10599971. DOI: 10.1111/1759-7714.15093.


Genetic alterations in juvenile cervical clear cell adenocarcinoma unrelated to human papillomavirus.

Su Y, Zhang Y, Zhou M, Zhang R, Chen S, Zhang L Front Med (Lausanne). 2023; 10:1211888.

PMID: 37654657 PMC: 10466801. DOI: 10.3389/fmed.2023.1211888.


Identification of hub genes and microRNAs with prognostic values in esophageal cancer by integrated analysis.

Mokhlesi A, Sharifi Z, Berimipour A, Taleahmad S, Talkhabi M Noncoding RNA Res. 2023; 8(3):459-470.

PMID: 37416747 PMC: 10319852. DOI: 10.1016/j.ncrna.2023.05.009.


Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma.

Ooki A, Osumi H, Chin K, Watanabe M, Yamaguchi K Ther Adv Med Oncol. 2023; 15:17588359221138377.

PMID: 36872946 PMC: 9978325. DOI: 10.1177/17588359221138377.


Network and pathway-based analysis of genes associated with esophageal squamous cell carcinoma.

He W, Yuan K, He J, Wang C, Peng L, Han Y Ann Transl Med. 2023; 11(2):102.

PMID: 36819552 PMC: 9929830. DOI: 10.21037/atm-22-6512.